Barry started his career at Merck nearly 28 years ago in Clinical Pharmacology, ultimately heading this department and all aspects of early development including a laboratory dedicated to biomarker evaluation and quantification. Over more than a decade, Barry participated in or directly supervised early development work on more than 80 new molecular entities. Barry’s portfolio subsequently expanded beyond early development and for12 years, as Senior Vice President, Global Clinical Development, Barry had oversight of those departments responsible for the design, analysis, reporting and execution of all clinical trials required for the registration and life cycle management of new molecules.

 Barry started his career at Merck nearly 28 years ago in Clinical Pharmacology, ultimately heading this department and all aspects of early development including a laboratory dedicated to biomarker evaluation and quantification. Over more than a decade, Barry participated in or directly supervised early development work on more than 80 new molecular entities. Barry’s portfolio subsequently expanded beyond early development and for12 years, as Senior Vice President, Global Clinical Development, Barry had oversight of those departments responsible for the design, analysis, reporting and execution of all clinical trials required for the registration and life cycle management of new molecules.